These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36135958)

  • 41. Early systemic sclerosis-opportunities for treatment.
    Sakkas LI; Simopoulou T; Katsiari C; Bogdanos D; Chikanza IC
    Clin Rheumatol; 2015 Aug; 34(8):1327-31. PubMed ID: 25711876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pigmented skin patches without scleroderma as a predominant clinical symptom revealing systemic sclerosis.
    Darrigade AS; Vedie AL; Gauthier C; Cario-André M; Taieb A; Truchetet ME; Constans J; Seneschal J
    Clin Exp Dermatol; 2016 Jun; 41(4):379-82. PubMed ID: 27171356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis.
    Li SC
    Pediatr Clin North Am; 2018 Aug; 65(4):757-781. PubMed ID: 30031497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How I treat patients with systemic sclerosis in clinical practice.
    Rossi D; Zanatta E; Marson P; Sciascia S; Polito P; Roccatello D; Cozzi F
    Autoimmun Rev; 2017 Oct; 16(10):1024-1028. PubMed ID: 28778710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis.
    Fang D; Chen B; Lescoat A; Khanna D; Mu R
    Nat Rev Rheumatol; 2022 Dec; 18(12):683-693. PubMed ID: 36352098
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Mimetics of systemic sclerosis].
    Jendrek ST; Kahle B; Riemekasten G
    Z Rheumatol; 2019 Feb; 78(1):14-23. PubMed ID: 30255410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Systemic sclerosis. Current classification and diagnosis of organ involvement].
    Persa OD; Moinzadeh P; Hunzelmann N
    Hautarzt; 2015 Aug; 66(8):599-603. PubMed ID: 26115973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mesenchymal stromal cells for systemic sclerosis treatment.
    Farge D; Loisel S; Lansiaux P; Tarte K
    Autoimmun Rev; 2021 Mar; 20(3):102755. PubMed ID: 33476823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic sclerosis.
    Asano Y
    J Dermatol; 2018 Feb; 45(2):128-138. PubMed ID: 29226387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic sclerosis-associated interstitial lung disease.
    Perelas A; Silver RM; Arrossi AV; Highland KB
    Lancet Respir Med; 2020 Mar; 8(3):304-320. PubMed ID: 32113575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Systemic sclerosis : What is currently available for treatment?].
    Becker MO
    Internist (Berl); 2016 Dec; 57(12):1155-1163. PubMed ID: 27796473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autoimmune disorders: nail signs and therapeutic approaches.
    Sherber NS; Wigley FM; Scher RK
    Dermatol Ther; 2007; 20(1):17-30. PubMed ID: 17403257
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting Costimulatory Pathways in Systemic Sclerosis.
    Boleto G; Allanore Y; Avouac J
    Front Immunol; 2018; 9():2998. PubMed ID: 30619351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of Alarmins in the Pathogenesis of Systemic Sclerosis.
    Giovannetti A; Straface E; Rosato E; Casciaro M; Pioggia G; Gangemi S
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.
    Taroni JN; Greene CS; Martyanov V; Wood TA; Christmann RB; Farber HW; Lafyatis RA; Denton CP; Hinchcliff ME; Pioli PA; Mahoney JM; Whitfield ML
    Genome Med; 2017 Mar; 9(1):27. PubMed ID: 28330499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sparing effect of hemiplegia on skin fibrosis and microvascular involvement: reports of two cases of systemic sclerosis and review of the literature.
    Ughi N; Hervey SA; Gualtierotti R; Silvana Z; Herrick AL; Ingegnoli F; Meroni P
    Semin Arthritis Rheum; 2015 Apr; 44(5):597-601. PubMed ID: 25488380
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MicroRNA-29: a potential therapeutic target for systemic sclerosis.
    Peng WJ; Tao JH; Mei B; Chen B; Li BZ; Yang GJ; Zhang Q; Yao H; Wang BX; He Q; Wang J
    Expert Opin Ther Targets; 2012 Sep; 16(9):875-9. PubMed ID: 22793265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Skin Histology in Systemic Sclerosis: a Relevant Clinical Biomarker.
    Showalter K; Gordon JK
    Curr Rheumatol Rep; 2020 Nov; 23(1):3. PubMed ID: 33244633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.
    Cavazzana I; Vojinovic T; Airo' P; Fredi M; Ceribelli A; Pedretti E; Lazzaroni MG; Garrafa E; Franceschini F
    Clin Rev Allergy Immunol; 2023 Jun; 64(3):412-430. PubMed ID: 35716254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.